Form 4 for LAB STANDARD BIOTOOLS INC.
Accepted 2025-08-05 00:00:00 ET · period of report 2025-08-01 · accession 0000950170-25-103296 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-08-05 | 2025-08-01 | LAB | Egholm Michael | Pres, CEO, Dir | A - Grant | $0.00 | +3.00M | 5.74M | +110% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-08-01 | A | A | 3,000,000 | $0.00 | 5,736,285 | D | — | — | (F1) Represents Restricted Stock Units ("RSUs") that vest as to 25% of the RSUs on August 1, 2026, with the remaining 75% of the RSUs vesting in three equal annual installments thereafter, subject to the Reporting Person's continued service through the applicable vesting date. Each RSU represents the right to receive one share of common stock upon vesting. (F2) Includes 5,000 shares previously acquired by the Reporting Person under the Issuer's Employee Stock Purchase Plan. |